Progression-free versus overall survival and adequate powering in randomised studies

European Journal of Cancer

Volumn 44, Issue 15, 2008, Pages 2092-2094

  Manek, Nishma ^a   Apostolopoulos, Christos ^a   Stebbing, Justin ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; PACLITAXEL;

ADD ON THERAPY; ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CONTROL GROUP; EDITORIAL; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HUMAN; MONOTHERAPY; MORBIDITY; MORTALITY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 53249121471     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.07.027     Document Type: Editorial

References (10)

1. Mc Guire W.P., Hoskins W.J., Brady Mr., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. New Engl J Med 334 (1996) 1-6
2. A'Hern R.P., and Gore M.E. Impact of Doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 13 (1995) 726-732
3. Fanning J., Bennett T.Z., and Hilgers R.D. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynaecol 80 (1992) 954-960
4. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma. A meta-analysis-ovarian-cancer meta-analysis project. J Clin Oncol 9 (1991) 1668-1674
5. US Department of Health and Human Services Food and Drug Administration: Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics; May 2007. .
6. Food and Drug Administration Centre for Drug Evaluation and Research, Oncologic Drugs Advisory Committee May 3-4 2004: Briefing Material: May 3, 2004, AM Session - Genasense. .
7. Du Bois A., Quinn M., Thigpen J., et al. Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC. Ann Oncol 16 Suppl. 8 (2005) viii7-viii12
8. Moss R. FDA approves Gemzar for ovarian cancer despite its lack of efficacy townsend letter, the examiner of alternative medicine; November 2006. .
9. Kristensen G.B., Vergote I., Eisenhauer E., et al. First line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs. TC): A Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG, and NCIC CTG - Results on progression free survival. J Clin Oncol 23 449s (2004) [suppl. abstr 5003]
10. du Bois A., Weber B., Rochon J., et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 24 7 (2006) 1127-1135